Details for Patent: 8,143,286
✉ Email this page to a colleague
Title: | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione) |
Abstract: | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. |
Inventor(s): | Jaworsky; Markian S. (Hopewell, NJ), Chen; Roger Shen-Chu (Edison, NJ), Muller; George W. (Bridgewater, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Filing Date: | Dec 15, 2008 |
Application Number: | 12/335,350 |
Claims: | 1. Crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate. 2. The dihydrate of claim 1, which has an X-ray powder diffraction pattern comprising peaks at approximately 20, 24.5 and 29 degrees 2.theta.. 3. The dihydrate of claim 1, which has an X-ray powder diffraction pattern comprising peaks at 20.0, 24.7 and 28.6 degrees 2.theta.. 4. The dihydrate of claim 1 corresponding to the representative X-ray powder diffraction patterns provided in FIGS. 23 and 35. 5. The dihydrate of claim 1, which has a differential scanning calorimetry thermogram comprising an endotherm at approximately 99.degree. C. 6. The dihydrate of claim 5, which has a differential scanning calorimetry thermogram further comprising an endotherm at approximately 269.degree. C. 7. The dihydrate of claim 1 corresponding to the representative differential scanning calorimetry thermograms provided in FIGS. 24 and 45. 8. The dihydrate of claim 1, which has a thermogravimetric analysis curve comprising a mass loss of about 12% up to about 175.degree. C. 9. The dihydrate of claim 1 corresponding to the representative thermal gravimetric analysis curves provided in FIGS. 24 and 40. 10. The dihydrate of claim 1, which does not exhibit a significant weight gain from 5% to 95% relative humidity. 11. The dihydrate of claim 1 corresponding to the representative moisture sorption/desorption isotherm provided in FIG. 25. 12. The dihydrate of claim 1 corresponding to the Form E intrinsic dissolution curves provided in FIGS. 53 and 54. 13. The dihydrate of claim 1 obtained by crystallization from a solvent system comprising a solvent selected from acetone and water. 14. A pharmaceutical composition comprising a therapeutically effective amount of the dihydrate of any one of claims 1, 2, 3, 4, 5, 6, and 7, and a pharmaceutically acceptable excipient, diluent, or carrier. 15. The pharmaceutical composition of claim 14, which is a single unit dosage form. 16. The pharmaceutical composition of claim 14, wherein the therapeutically effective amount is about 5 mg. 17. The pharmaceutical composition of claim 14, wherein the therapeutically effective amount is about 10 mg. 18. The pharmaceutical composition of claim 14, wherein the therapeutically effective amount is about 25 mg. 19. The pharmaceutical composition of claim 14, wherein the therapeutically effective amount is about 50 mg. |